The Journal of Psychoactive Drugs publishes a peer-reviewed study from the Ketamine Research Foundation on how long ketamine is present in breast milk

The research opens the door to ketamine-assisted psychotherapy (KAP) as a first-line antidepressant for breastfeeding women with postpartum depression (PPD).

SAN FRANCISCO, August 08, 2022–(BUSINESS WIRE)–The Ketamine Research Foundation, an organization dedicated to realizing the promise of ketamine as assisted psychotherapy, announced that its research paper Pharmacokinetics of ketamine in the breast milk of lactating women: quantification of ketamine and metabolites was published in the highly respected Journal of Psychoactive Drugs. The research, available here, provides the basis for investigating the use of ketamine in the postpartum period as an option for women who do not want to expose infants to conventional antidepressants through breast milk. Ketamine is recognized as the first-line treatment for depression.

The research provides the first quantification of ketamine and its major metabolites in human breast milk. Its results demonstrate a rapid decrease in the presence of ketamine a few hours after administration. The results provide evidence to support rapid and safe resumption of breastfeeding for nursing mothers using ketamine, thus sparing infant exposure.

“The Ketamine Research Foundation believes this study will open the door to further explorations of ketamine in the treatment of postpartum emotional disorders,” said Dr. Philip Wolfson, CEO of the Ketamine Research Foundation and widely recognized leader. in development. ketamine-assisted psychotherapy. “The Ketamine Research Foundation is in the process of developing its protocol for postpartum depression and plans to launch it in the fall of 2022.”

About the Journal of Psychoactive Drugs

An authoritative, peer-reviewed periodical containing timely information of a multidisciplinary nature for clinicians and other professionals in the substance abuse field; the Journal of Psychoactive Drugs was the first journal established in the United States to focus on psychoactive drug abuse and continues to introduce groundbreaking work on topics such as drug use and crime, therapeutic communities, dual diagnosis, psychotherapy/counselling, drug treatment, and culturally appropriate addiction treatment.

About the Ketamine Research Foundation

Ketamine is the only legally available drug with psychoactive psychedelic properties. The Ketamine Research Foundation is at the pinnacle of ketamine research and ketamine psychotherapy. We are the ground on which the practices of psychedelic psychotherapy are born and mature, the first in the toolbox, the basis for the development of great practices beneficial to human beings. For more information, please visit

See the source version on


Media Contact:
Rick Keating
[email protected]
(917) 767-2400

Alvin J. Chase